Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2068

1.
2.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
3.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
4.

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Cremonini F, Delgado-Aros S, Camilleri M.

Neurogastroenterol Motil. 2003 Feb;15(1):79-86.

5.

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.

PMID:
15290660
6.

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.

Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P.

Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. doi: 10.1038/ajg.2009.223. Epub 2009 May 26. Review.

PMID:
19471254
7.

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID:
15654790
8.

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003960. Review.

PMID:
17943807
9.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.

Am J Gastroenterol. 2004 Nov;99(11):2195-203.

PMID:
15555002
10.

Tegaserod for the treatment of irritable bowel syndrome.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2004;(1):CD003960. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD003960.

PMID:
14974049
11.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team.

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
12.

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.

Am J Gastroenterol. 2001 Mar;96(3):803-11.

PMID:
11280555
13.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

14.
15.

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.

Chang L, Tong K, Ameen V.

Am J Gastroenterol. 2010 Apr;105(4):866-75. doi: 10.1038/ajg.2010.25. Epub 2010 Mar 2.

PMID:
20197759
16.

Alosetron and irritable bowel syndrome.

Mayer EA, Bradesi S.

Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. Review.

PMID:
14596662
17.

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D; Lotronex Investigator Team.

Am J Gastroenterol. 2002 Dec;97(12):3139-46.

PMID:
12492201
18.

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.

Chey WD, Cash BD.

Expert Opin Investig Drugs. 2005 Feb;14(2):185-93. Review.

PMID:
15757394
19.
20.

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.

Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M.

Dis Colon Rectum. 2008 Dec;51(12):1775-80. doi: 10.1007/s10350-008-9335-z. Epub 2008 May 9.

PMID:
18465170

Supplemental Content

Support Center